07:39 AM EDT, 10/30/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q3 adjusted loss Wednesday of $0.05 per diluted share, wider than the loss of $0.03 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.05.

Total operating expenses for the quarter ended Sept. 30 were $58.1 million, up from $20.7 million a year earlier.

As of Sept. 30, the company said it had $487 million in cash and or cash equivalents on hand.

Price: 21.52, Change: -0.31, Percent Change: -1.42